Title
Category
Credits
Event date
Cost
Digital Pathway - Navigating the Diagnosis and Management of Heart Failure in Women: Identifying and Understanding the Gaps to Improve Outcomes
  • CMHC
  • 1.00 ABIM MOC and AMA PRA Category 1 Credit™
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with heart failure. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), and despite a higher HF symptom burden, they are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps. In recent years, significant advances in the prevention and treatment of HF have been made, all with the potential to alter treatment paradigms now and in the future.
Escape Room Experience: Challenges and Advances in the Management of Anemia of CKD
  • CMHC
  • 1.25 ABIM MOC and AMA PRA Category 1 Credit™
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
$0.00
Anemia is a common comorbidity in patients with chronic kidney disease (CKD), and is associated with significant morbidity and impacts on quality of life. The complicated pathophysiology of the condition and the disadvantages associated with current treatments are some of the major barriers that clinicians face in reducing the burden of anemia in patients with CKD.
Escape Room Experience: LDL-Lowering Therapy and Beyond - Applying Advances to Patient Care
  • CMHC
  • 1.25 ABIM MOC and AMA PRA Category 1 Credit™
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
$0.00
Lowering LDL-C effectively and safely is crucial to prevent and lower the risk of adverse cardiovascular events, however, LDL-C goal achievement remains suboptimal, including in high-risk and very high-risk patients. The landscape of LDL-C lowering therapy has significantly evolved, with new consensus statements, newer agents, as well as important evidence that may help address some of the current gaps. Additionally, there is residual risk beyond LDL-C, including elevated triglyceride levels and elevated Lp(a).
Webcast: Identifying and Addressing Elevated Sodium Intake to Decrease Cardiovascular Risk
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), Additionally, the impact of commonly-used medications with high sodium content contributes to this burden.  As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including in patients with sleep disorders, as well as practical strategies to minimize the impact of elevated sodium.
Ace the Case Challenge Series: Sodium Intake and CV Risk
  • CMHC
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
$0.00
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), Additionally, the impact of commonly-used medications with high sodium content contributes to this burden.  As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including in patients with sleep disorders, as well as practical strategies to minimize the impact of elevated sodium.
The Role of TAVR in Improving Outcomes in Women with Aortic Stenosis: Assessing the Evidence and Clinical Pearls
  • CMHC
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Despite advances, there are significant gaps in the diagnosis and treatment of aortic stenosis (AS) in women. Transcatheter aortic valve replacement (TAVR) has emerged as a viable treatment option in this setting, having demonstrated increased efficacy and safety for the treatment of AS in women. This activity covers important updates in the screening, diagnosis, and risk stratification of women with AS, as well as practical considerations for TAVR.
Sleep, Sodium, and CVD - A Cardiology Perspective
  • CMHC
  • 2.25 ACPE Pharmacy
  • 2.25 AMA PRA Category 1 Credit™
  • 2.25 ANCC
  • 2.25 Participation
$0.00
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), including in the development of hypertension and risk of adverse cardiovascular outcomes. Additionally, the impact of commonly-used medications with high sodium content contributes to this burden. As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including patients with insufficient or impaired sleep, as well as practical strategies to minimize the impact of elevated sodium.
New Hope on the Horizon - Advances in the Diagnosis and Treatment of Idiopathic Hypersomnia
  • CMHC
  • 1.75 ACPE Pharmacy
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC
  • 1.75 Participation
$0.00
Idiopathic hypersomnia (IH) is a chronic neurological disorder that has significant impacts on daily functioning, with symptoms that include, but often go beyond excessive daytime sleepiness (EDS). Overall awareness about IH remains low, which contributes to the suboptimal recognition of this condition, which is often exacerbated by insufficient diagnostic criteria leading to delayed diagnosis and treatment.
Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
This activity consists of a recorded presentation at the 18th annual CMHC Annual Congress held from October 18-21, 2023, in Boston, MA. The session, “Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults: Perspectives & Advances,” was presented by Keith C. Ferdinand, MD, and Debbie Cohen, MD. Drs. Ferdinand and Cohen discussed:The strategies to overcome barriers to hypertension control and cardiovascular diseases.The definitions, current treatment, and emerging approaches for resistant hypertension.
Challenges and Solutions in Lipid-Lowering Therapy in Women: From Gaps to Practice-Changing Advances
  • CMHC
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC
  • 1.50 Participation
$0.00
Atherosclerotic cardiovascular disease (ASCVD) events are among the leading causes of death in women in the US and globally. Even with advances in LDL-C (low-density lipoprotein cholesterol) lowering therapy, LDL-C goal achievement in high-risk women is lower than that in men, with clinical inertia, statin intolerance, and non-adherence being major factors.

Pages